Teplizumab (TZIELD) — T1D Delay Now Available

Type: drug

Status: Approved and available

Developer: Provention Bio / Sanofi

Breakthrough Summary

First FDA-approved therapy to delay onset of clinical Type 1 diabetes in at-risk individuals (Stage 2, autoantibody-positive). Delays T1D onset by median 2+ years.

Mechanism of Action

Anti-CD3 monoclonal antibody that delays onset of clinical Type 1 diabetes in at-risk individuals

Year: 2025-2026